Prostate Specific Antigen, Human (PSA, Kallikrein-3, Seminin, Semenogelase, g-Seminoprotein, KLK3) BioAssay(TM) ELISA Kit

Intended use for the quantitative \ndetermination of PSA in human serum. \n\nHuman prostate-specific antigen (PSA) is a serine protease, a sigle chain glycoprotein with a molecular weight of approximately 34kD containing 7% carbohydrate by weight. PSA is immunologically specific for prostatic tissue, it is present in normal, benign hyperplastic, and malllignant prostatic tissue, in metastatic prostatic carcinoma, and also in prostatic fluid and seminal plasma. PSA is not present in any other normal tissue obtained from men, nor is it produced by cancers of the breast, lung, colon, rectum, stomach, pancreas or thyroid. Besides, it is functionally and immunologically different from prostatic acid phosphatase (PAP). Elevated serum PSA concentrations have been reported in patients with prostate cancer, benign prostatic hypertrophy, or inflammatory conditions of other adjacent genitourinary tissues, but not in apparently healthy men, men with non-prostatic carcinoma, apparently healthy women, or women with cancer. Reports have suggested that serum PSA is one of the most useful tumor markers in oncology. It may serves as an accurate marker for assessing response to treatment in patients with prostatic cancer. Therefore, measurement of serum PSA concentrations can be an important tool in monitoring patients with prostatic cancer and in determining the potential and actual effectiveness of surgery or other therapies. Recent studies also indicate that PSA measurements can enhancce early prostate cancer detection when combined with digital rectal examination (DRE). \n\nDetection Range: 0-100ng/ml\n\nSample: ~50ul serum \n\nSpecificity: ~98.7% \n\nSensitivity: ~0.5ng/ml \n\nTotal Time: ~ 140 min \n \nKit Components: \nEach kit contains the following components in sufficient quantities to perform the number of tests indicated. All reactive reagents contain 0.1% sodium azide as a preservative.\n1. Microtiter Plate\n2. Conjugate\n3. Calibrator\n4. Positive Control\n5. Negative Control\n6. TMB\n7. Wash Buffer, 10X Diluted wash buffer to 1X\n8. Sample Diluent\n9. Stop Solution \n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

P9054-14

Size

1Kit

Applications

ELISA

References

1. Hara, M et. al., Two prostate-specific antigens, gamma-seminoprotein and beta-microseminoprotein. J. Lab. Clin. Med. 113:541-548;1989. 2 Yuan, J.J et. al., Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J. Urol. 147:810-814; 1992. 1. Wang, M.C et. al., Prostatic antigen: a new potential marker for prostatic cancer. Prostate 2:89-93; 1981. 053199 2. Stowell, L.I. et. al., An Enzyme-Linked Immunosorbent Assay ( ELISA ) for Prostate-specific antigen. Forensic Science Intern. 50:125-138; 1991. 3. Frankel, A.E. et. al., Monoclonal antibodies to a human prostate antigen. Canc. Res. 42:3714; 1982. 4. Benson, M.C. et. al., Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol. 147:815-816; 1992. 5. Gorman, C. The private pain of prostate cancer. Time 10(5):77- 80; 1992. 6. Walsh, P.C. Why make an early diagnosis of prostate cancer. J. Urol. 147:853-854; 1992. 7. Labrie, F. et. al., prostate specific antigen as pre-screening test for prostate cancer. J. Urol. 147:846-852; 1992. 8. McCarthy, R.C. et. al., Human prostate acid phosphatase : purification, characterization, and optimization of conditions for radioimmunoassay. Clin. Chim. Acta. 132:287-293; 1983. 9. Heller, J.E. Prostatic acid phosphase: its current clinical status. J. Urol. 137:1091-1099; 1987. 10. Filella, X. et. al., Clinical usefulness of prostate-specific antigen. Tumor Biol. 11:289-294; 1990. 11. Shin, W.J. et. al., Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements. J. Nat. Med. Assoc. 84:1049-1050; 1992. 12. Wirth, M.P. and Frohmuller, H.G. Prostate-specific antigen and prostate acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases. Eur. Urol. 21:263-268; 1992. 13. Campbell, M.L. More cancer found with sensitive PSA assay. Urol. Times. 20:10; 1992. 14. Vessella, R.L. et. al., Evaluation of the Abbott IMx Automated immunoassay of Prostate-Specific Antigen. Clin. Chem. 38:2044-2054; 1992. 15. Brawer, M.K. et. al., Screening for prostatic carcinoma with prostate specific antigen. J. Urol. 147:841-845; 1992. 16. Benson, M.C. et. al., The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 147:817-821; 1992. 19. Oesterling, J.E. et. al., PSA still finding niches in cancer diagnosis. Urol. Times 20:13- 18; 1992. 20. Babaian, R.J. et. al., Prostate-specific antigen and the prostate gland \nvolume: correlation and clinical application. J. Clin. Lab. Anal. 4:135-137; 1990.